Oncology Views & Analysis | pharmaphorum

Saturday 7 February 2026

Views & Analysis

Deep Dive

Revealing the true value of new cancer drugs to payers

Revealing the true value of new cancer drugs to payers

Marc Botteman and Ben van Hout from Pharmerit International discuss how to navigate the value challenges of new cancer treatments like CAR-T with payers.

Views & Analysis

pharmaphorum_podcast-Episode-14-1200x675

AstraZeneca and lung cancer: the pharmaphorum podcast

This episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, global franchise head, Tagrisso TDR (Tumour Drivers and Resistance) Patrick Connor explaining why the

Views & Analysis

Adapting for the future of clinicial trials

Adapting for the future of oncology trials

Advanced analytical solutions provider Cytel is at the forefront of rapid changes in oncology R&D.

Deep Dive

Moving from autologous to allogeneic ACT paradigms

Moving from autologous to allogeneic ACT paradigms

We have come so far in a relatively short time with Adoptive Cellular Transfer (ACT).

Deep Dive

Did cancer clinical trials stay on track at ASCO 2019

Did cancer clinical trials stay on track at ASCO 2019?

Chicago is recovering after 40,000 oncologists and cancer experts descended on the city for this year’s ASCO conference.

Deep Dive

Why pharma needs honest patient dialogue

Why pharma needs honest patient dialogue

Astellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the patient experience.